BOLD News and Press, Audentes Therapeutics Inc.

Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer,...

2024-05-13 09:47:09 ET More on Boundless Bio, Inc. Boundless Bio Starts $100 Million U.S. IPO Plan Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO Boundless Bio prices $100M IPO at $16 per share Historical earnings data for Boundless Bio, Inc. ...

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications ...

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will...

2024-04-21 06:46:42 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead

STARMAP ( S tudy T reating A cquired R esistance: M APK A m p lifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies BBI-825 is a novel, oral, selective ribonucleotide redu...

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers Third poster presentation to highlight the potential role of ...

2024-03-30 01:00:00 ET Summary Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings - Boundless Bio, U-BX Technology, Alta Global, and IB Acquisition, respectively. Three IPOs submitted initial filings this week - Marex Group, Reitar Logtech a...

2024-03-28 13:51:03 ET More on Boundless Bio, Inc., Renaissance Capital Greenwich Funds - Renaissance IPO ETF, etc. Read the full article on Seeking Alpha For further details see: Bayer-backed Boundless Bio stock down 8% after $100M IPO

Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 ...